Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    15201414 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Suspended Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Rituximab
2 Completed
Has Results
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Conditions: Anemia, Aplastic;   Red-Cell Aplasia, Pure;   Anemia, Diamond-Blackfan
Intervention: Drug: Rituximab
3 Completed Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Anti-CD20 (rituximab)
4 Unknown  Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Condition: Ankylosing Spondylitis
Intervention: Drug: rituximab

Indicates status has not been verified in more than two years